Cargando…
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 7...
Autores principales: | Harder, Thomas, Külper-Schiek, Wiebe, Reda, Sarah, Treskova-Schwarzbach, Marina, Koch, Judith, Vygen-Bonnet, Sabine, Wichmann, Ole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518304/ https://www.ncbi.nlm.nih.gov/pubmed/34651577 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.41.2100920 |
Ejemplares similares
-
Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021
por: Harder, Thomas, et al.
Publicado: (2021) -
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021) -
Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
por: Külper-Schiek, Wiebe, et al.
Publicado: (2022) -
Authors’ response: Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: More data on asymptomatic SARS-CoV-2 infection
por: Harder, Thomas, et al.
Publicado: (2021) -
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
por: de Gier, Brechje, et al.
Publicado: (2021)